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Abstract
The aim of this study was to enhance the low solubility of eflucimibe, a new chemical entity which can be used as medicine to treat 
dyslipidemiae, by complexation with !-cyclodextrin. The complex was prepared using kneading method. The interaction evolution was 
studied during process by comparison of the semi-solid and physico-chemical states of the product. The evolution of the semi-solid state 
was followed by torque measurement when the evolution of physico-chemical state was studied by differential scanning calorimetry, infrared 
spectroscopy and by determination of the drug solubilisation profile. The interaction, which occurs during the process, is characterised by a 
modification of the product consistency and by a disappearance of the drug endothermic peaks, a disappearance of a drug spectral band and a 
widely improvement of the drug solubilisation profile. Indeed, after complete interaction, the drug quantity solubilised in specific conditions 
increased about 44-fold compared to those of untreated drug. Moreover, the comparison of the physico-chemical and semi-solid states during 
kneading process clearly shows that when the interaction takes place, a solidification of the paste occurs. The results of these works suggested 
that the formation of new solid phase allows an enhancement of the solubility of eflucimibe.
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1. Introduction
New chemical entities are more and more poorly soluble
in water (Lipinski, 2001, 2002). As a consequence, these
compounds are not easy to develop as drug products us-
ing traditional formulation methods. Different formulation
approaches (Panchagnula and Thomas, 2000) are gener-
ally used to overcome these difficulties: generation of salts
(Berge et al., 1977); micronization (Boulay, 1985); use of
complexing agent such as cyclodextrins (Ducheˆne et al.,
1985); nanosizing (Merisko-Liversidge et al., 2003); melt
extrusion (Breitenbach, 2002), etc. One of the difficulties
is to generate a stable formulation and to use a process
compatible with a future scaling-up.
This paper will focus on the preparation of a complex
between a new chemical entity, eflucimibe (Patoiseau et al.,
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1997), in the presence of !-cyclodextrin, using a kneading
method.
Cyclodextrins are cyclic oligosaccharides able to
host in their cavity, which is prevailingly hydrophobic,
molecules of various kinds, thus affecting the physical and
physico-chemical properties (e.g. solubility, stability, . . . )
of the guest, and ultimately, in the case of drugs, its bioavail-
ability and therapeutic efficiency (Loftsson and Brewster,
1996).
Eflucimibe [S-2′,3′,5′-trimethyl-4′-hydroxy-"-dodecyl-
thio-phenylacetanilide] is a dodecylthio-phenylacetanilide
derivative (molecular weight = 469.73 gmol− 1) whose
schematic structure is reported in Fig. 1. This drug, which
can be used as medicine especially to treat dyslipidemiae,
is characterized by its very poor solubility in water. This
causes interindividual variations of its low bioavailability.
The complexation with cyclodextrins may be expected to
overcome these disadvantages.
The present paper is orientated to the investigation
of the complexation feasibility between eflucimibe and
Fig. 1. Schematic structure of eflucimibe.
!-cyclodextrin using the kneading method. The operating
conditions implemented in the presented study have been
optimised (Bougaret et al., 2002) and should be shortly
published. In order to characterize interaction between
active pharmaceutical ingredient and cyclodextrin, dif-
ferential scanning calorimetry, infrared spectroscopy and
determination of eflucimibe solubilisation kinetics were
used.
2. Materials and methods
2.1. Materials
Eflucimibe was manufactured and supplied by Pierre
Fabre Laboratories (Castres, France). !-Cyclodextrin was
purchased from Wacker-Chemie GmbH (München, Ger-
many) and used as received, i.e. by taking into account
water content.
2.2. Preparation of binary systems
Gamma-cyclodextrin was put in the Kneader bowl kept
at 35 ◦C and wet with purified water. The quantity of puri-
fied water added was calculated in order to obtain a mix-
ture containing 25% of total water. After 5min, when the
aqueous slurry of cyclodextrin was homogeneous, eflucim-
ibe was added and the blend was kneaded thoroughly. The
quantity of eflucimibe added was calculated in order to ob-
tain an eflucimibe:cyclodextrin molar ratio of 1:2. For each
sample taken, the paste obtained was dried at 40 ◦C for
12 h using a vacuum oven. The dried product was sieved
below 300mesh. The kneading device used was a Braben-
der rheometer with Banbury blades (Z-shaped). The rotation
speed of the blades was fixed at 30 rpm. The viscosity of
the system was followed during kneading step by the torque
measurement following internal calibration.
2.3. DSC and thermoanalytical procedure for the
determination of the percentage of transformed
eflucimibe (Y)
Thermal analysis by DSC was carried out using a
Perkin-Elmer DSC 7 apparatus. Samples of 3mg were
put into aluminium pans. These pans were not sealed
in order to permit the loss of gases evolved during the
heating process. DSC scans were performed in tripli-
cate under nitrogen, at a heating rate of 10 ◦Cmin− 1
in the temperature range of 30–280 ◦C. Heats of fusion
were automatically determined by the software follow-
ing calibration with indium (28.4 J g− 1), using integra-
tion of the areas under the DSC endothermic peaks of
melting.
A thermoanalytical procedure can be applied to quantify
the interaction yield (Giordano et al., 1992; Ginés et al.,
1998). F is the fraction by weight of eflucimibe in the start-
ing mixture and N is the fraction by weight of eflucimibe
in the initial state after the kneading step. The percentage
of transformed eflucimibe after interaction, Y, is calculated
according to Eq. (1)
Y = 100 − 100
(
N
F
)
(1)
where N is calculated according to DSC results and Eq. (2)
N = !Heflucimibe melting after kneading step
!Hpure eflucimibe melting
(2)
2.4. FTIR spectroscopy and spectroscopic procedure to
follow eflucimibe interaction
The infrared spectra were recorded on a Nicolet FTIR
spectrometer. The analysed component was dispersed in KBr
medium in solid state before acquisition.
For many drugs, the formation of a complex with cy-
clodextrin can lead to a modification of IR spectrum (Lin
and Perng, 1992). As presented hereafter, eflucimibe in-
teraction with cyclodextrin led to a decrease of eflucimibe
band intensity. In order to quantify this modification, the
Beer–Lambert law was applied by the determination of log
I0/I with I0 corresponding to the absorbance at 1572 cm− 1
(spectral region where eflucimibe and cyclodextrin do not
present spectral band) and I corresponding to absorbance at
1537 cm− 1 (spectral region where only eflucimibe presents
spectral band).
2.5. Determination of eflucimibe solubilisation kinetics
The eflucimibe solubilisation kinetics were determined
with samples corresponding to 50mg of eflucimibe. These
samples were added to 100ml of the solubilisation medium
corresponding to an aqueous solution containing 5% (w/v)
of sodium lauryl sulfate. The samples were continuously
stirred while remaining in a water bath at 37 ◦C. At var-
ious time intervals, samples were withdrawn and filtered
through 0.45#m membrane. The amount of eflucimibe
dissolved was determined by HPLC using UV detection
at 220 nm. Acetonitrile and purified water at 82:18 (v/v)
was run at 1mlmin− 1 flow rate through a reverse-phase
C8 column.
Fig. 2. Evolution of the torque applied during kneading of eflucimibe:
!-cyclodextrin aqueous mixture.
3. Results and discussion
3.1. Evolution of product semi-solid state during kneading
process
The evolution of the torque applied in order to keep con-
stant the rotation speed of the blades during the kneading
process is presented in Fig. 2. As the torque is directly linked
to the product viscosity, this evolution shows that the prod-
uct semi-solid state changes during the process.
This evolutionmay be divided into four steps. The first one
(I, 0–5min) corresponds to the homogeneisation of aque-
ous !-cyclodextrin slurry. The second begins at the time of
eflucimibe addition. Eflucimibe was added to the mixture
within approximately 1min. This second step (II, 5–20min),
for which the torque slightly decreases, corresponds to the
preparation and the homogeneisation of the aqueous eflucim-
ibe: !-cyclodextrin mixture. Then, the third (III, 20–33min)
is characterised by a sharply increase of the product viscos-
ity, corresponding to a solidification of the semi-solid form.
The fourth (IV, 33–50min) begins to the apex of the torque
curve and is characterised by a large decrease of torque. It
may be attributed to the breaking-up of the product after
solidification.
During the kneading process, several samples (referenced
A–F) have been taken (Fig. 2) and have been characterised
by determination of water content, DSC, FTIR and by de-
termination of eflucimibe solubilisation kinetics.
3.2. Evolution of product physico-chemical state during
kneading process
In order to verify if the torque increase observed during
kneading process was due to water evaporation or not, the
determination of water content using Karl Fischer method
was performed in samples taken before and after solidifica-
tion (samples A and F, respectively). The results obtained,
Fig. 3. Differential scanning calorimetry curves of: (I) pure eflucimibe;
(II) !-cyclodextrin; (III) 1:2 eflucimibe: !-cyclodextrin physical mixture.
23.7% for sample A and 22.7% for sample F, showed no
significant change of water content during kneading. This
result demonstrated that the modification of semi-solid state
during kneading was not due to a loss of water.
The thermal profiles of eflucimibe, !-cyclodextrin and
eflucimibe: !-cyclodextrin physical mixture are reported in
Fig. 3.
The eflucimibe DSC curve exhibits four endothermic
peaks described in Table 1.
The thermal behavior of !-cyclodextrin is characterised
by a broad endotherm in the 50–130 ◦C range, which can be
attributed to water loss. The DSC profile of the 1:2 eflucim-
ibe: !-cyclodextrin physical mixture corresponds to a stack-
ing of endotherms of each constituent. Fig. 4 presents the
evolution of the kneaded product thermal behavior during
kneading process.
Even if the interaction occurring during kneading process
leads to a disappearance of all eflucimibe endotherms, the
thermoanalytical procedure was performed considering only
Table 1
Characteristics of eflucimibe endothermic peaks
Endotherm Attribution Peak characteristics
TONSET (◦C) !H (J g− 1)
a Solid–solid transition 78.4 − 11.5
b Solid–solid transition 111.4 − 35.9
c Solid–solid transition 117.7 − 3.1
d Melting 129.6 − 76.4
Fig. 4. Evolution of DSC curve during kneading process.
eflucimibe melting peak. The enthalpies relative to the melt-
ing event of eflucimibe were evaluated and the percentages
of eflucimibe transformed during kneading were calculated
and are presented in the Table 2. This characterisation shows
that the interaction between eflucimibe and !-cyclodextrin
takes place during the solidification of the system and is op-
timal at the end of this one. Before the solidification, in the
second step, the weak decrease in the enthalpy is probably
due to the dispersion of eflucimibe within the slurry. After
this one, in the fourth step, the transformation of eflucimibe
by !-cyclodextrin does not change; only the consistency of
the mixture evolves.
Fig. 5 shows spectra of pure eflucimibe, !-cyclodextrin
and eflucimibe: !-cyclodextrin physical mixture, which cor-
responds to superposition of IR absorption bands of each
constituent. In the stretching region near 1540 cm− 1, the
!-cyclodextrin poorly absorbs while eflucimibe exhibits an
intense band located at 1537 cm− 1 corresponding to N–H
bond. The spectroscopic procedure was performed accord-
ing to the intensity of this band.
The evolution of the IR spectrum of the mixture during
the kneading process is shown in Fig. 6.
For the samples taken during the second step, the IR spec-
trum of the mixture is similar to the corresponding physical
Table 2
Evolution of the enthalpy relative to the eflucimibe melting and of the
percentage of eflucimibe transformed during kneading process
Sample !Heflucimibemelting of kneaded product
(J g− 1)
Percentage of
transformed eflucimibe
A − 8.4 20
B − 8.1 25
C − 6.6 39
D − 1.7 85
E − 0.5 96
F − 0.2 99
Fig. 5. FTIR spectra of: (I) pure eflucimibe; (II) !-cyclodextrin; (III) 1:2
eflucimibe: !-cyclodextrin physical mixture.
mixture (A and B). During the solidification, the IR spectra
of the samples show a progressive decrease in the intensity
of the eflucimibe band located at 1537 cm− 1 (C and D) up to
disappearance (E). In the fourth step, the IR spectrum does
Fig. 6. Evolution of IR spectrum during kneading process.
Table 3
Evolution of log I0/I relative to eflucimibe band located at 1537 cm− 1
Sample A B C D E F
Log I0/I 0.128 0.123 0.109 0.055 0.037 0.037
Fig. 7. Representation of DSC results in relation to IR results.
not change (F). The Table 3 presents the evolution of log
I0/I, which is directly linked to the intensity of eflucimibe
band located at 1537 cm− 1.
These results confirm the previous ones obtained by
DSC. Indeed, the quantitative evaluation of the interac-
tion between eflucimibe and !-cyclodextrin by IR shows
that the interaction occurs during the solidification. More-
over, the representation presented in Fig. 7 of the percent-
age of transformed eflucimibe (DSC results) according
to the log I0/I (IR results) is a straight line that demon-
strates the correlation between the characterisation methods
implemented.
Fig. 8. Evolution of eflucimibe solubilisation kinetics during kneading process.
Fig. 9. Representation of DSC results and IR results in relation to solu-
bilisation kinetics results.
The eflucimibe solubilisation kinetics were evaluated for
all samples taken during the kneading process and are pre-
sented in Fig. 8.
The eflucimibe solubilisation kinetics are weakly im-
proved compared to the corresponding physical mixture for
the samples taken during the second step (A and B). For the
samples taken during the solidification, in the third step, the
eflucimibe solubilisation kinetics progressively improves.
Indeed, the quantity of eflucimibe in solution after 120min
is increased by 8, 32 and 43 times compared to the corre-
sponding physical mixture for, respectively, the samples C,
D and E. For the sample taken after solidification (F), the
eflucimibe solubilisation kinetic is nearly the same as that
of the sample taken to the apex of the viscosity curve (E).
The quantity of eflucimibe in solution after 120min showed
a 44-fold increase compared to the physical mixture.
Fig. 10. Representation of the evolution of physico-chemical and
semi-solid states of the eflucimibe: !-cyclodextrin mixture during knead-
ing process.
These confirm the results obtained by DSC and IR spec-
troscopy as shown in the Fig. 9.
3.3. Comparison of physico-chemical and semi-solid states
of the product during kneading process
Fig. 10, which presents physico-chemical state in relation
to semi-solid state of the product during kneading process,
clearly shows that the molecular interaction occurring be-
tween eflucimibe and !-cyclodextrin is directly linked to the
solidification of the paste.
This study clearly shows that the complexation between
eflucimibe and !-cyclodextrin by kneading method corre-
sponds to a reactive mixing, which may be divided into two
successive main steps as schematized in Fig. 11. The first
Fig. 11. Scheme of successive main steps occurring during kneading
process.
one, which begins at the end of eflucimibe addition and fin-
ishes when solidification begins, corresponds to a step where
the constituents remain in presence before expressing an in-
teraction. This could be considered as an induction step. Af-
ter that, from the start to the end of the solidification step,
the formation of eflucimibe: !-cyclodextrin complex occurs.
4. Conclusion
The formation of a complex between the hypolipidemic
eflucimibe and !-cyclodextrin has been studied by kneading
method. In the solid state, using DSC, FTIR and the deter-
mination of eflucimibe solubilisation kinetics, the feasibility
of a complex with !-cyclodextrin has been shown. More-
over, the formation of eflucimibe: !-cyclodextrin complex
in a molar ratio 1:2 leads to a large improvement of eflucim-
ibe solubilisation characteristics, which allowed the possibil-
ity that a formulation containing eflucimibe: !-cyclodextrin
complex obtained using kneading process should improve
the eflucimibe bioavailability.
Finally, this study clearly shows the interest of using
torque measurement to follow up the transformation of the
product during the kneading process. Indeed, the solidifica-
tion of the mixture can be used to monitor the interaction of
eflucimibe with !-cyclodextrin.
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